On Thursday, Stoke Therapeutics hit an important technical milestone, with its Relative Strength (RS) Rating entering into the 90-plus percentile with an improvement to 94, an increase from 87 the day before.
Here Are 3 Keys For Successful Stock Investing
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against all other stocks in our database.
History shows that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 in the early stages of their moves.
While now is not an ideal time to invest, see if the stock manages to form a consolidation and break out.
Stoke Therapeutics reported 0% earnings growth in the latest quarterly report. Revenue gains came in at 186%.
The company earns the No. 24 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
